BioAge Labs (NASDAQ: BIOA) shares have surged by 122% this year due to progress in weight management therapeutics. However, with only one candidate in phase 1 of clinical trials, the stock remains risky. Analysts project rapid growth in the weight management sector, but BioAge Labs faces tough competition from major pharmaceutical companies.

Investors may want to steer clear of BioAge Labs due to its risky position in the industry. While the weight management niche is growing, BioAge Labs lacks the proven track record of more established biotechs like Viking Therapeutics. With only one candidate in phase 1 trials, the stock’s success remains uncertain.

Viking Therapeutics, a clinical-stage biotech, offers a less risky alternative to BioAge Labs. With lead candidate VK2735 in phase 3 trials after successful phase 2, Viking Therapeutics presents a more stable investment opportunity. While BioAge Labs may have potential upside, investing in Viking Therapeutics may offer more security for the long term.

Read more at Yahoo Finance: 2 Reasons I Wouldn’t Touch BioAge Labs Stock With a 10-Foot Pole